HRP20210466T1 - Farmaceutski sastav za sprječavanje debljanja uzrokovanog načinom prehrane - Google Patents
Farmaceutski sastav za sprječavanje debljanja uzrokovanog načinom prehrane Download PDFInfo
- Publication number
- HRP20210466T1 HRP20210466T1 HRP20210466TT HRP20210466T HRP20210466T1 HR P20210466 T1 HRP20210466 T1 HR P20210466T1 HR P20210466T T HRP20210466T T HR P20210466TT HR P20210466 T HRP20210466 T HR P20210466T HR P20210466 T1 HRP20210466 T1 HR P20210466T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- weight
- range
- composition according
- natural
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 15
- 208000008589 Obesity Diseases 0.000 title 1
- 230000037213 diet Effects 0.000 title 1
- 235000005911 diet Nutrition 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 10
- 239000003963 antioxidant agent Substances 0.000 claims 6
- 230000003078 antioxidant effect Effects 0.000 claims 6
- 235000006708 antioxidants Nutrition 0.000 claims 6
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims 6
- 239000000314 lubricant Substances 0.000 claims 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims 4
- 239000008187 granular material Substances 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims 2
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims 2
- 239000003940 fatty acid amidase inhibitor Substances 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims 2
- 235000008975 pantethine Nutrition 0.000 claims 2
- 229960000903 pantethine Drugs 0.000 claims 2
- 239000011581 pantethine Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 claims 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims 1
- JFACETXYABVHFD-WXPPGMDDSA-N Pristimerin Chemical compound CC1=C(O)C(=O)C=C2[C@@](CC[C@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C[C@H]53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-WXPPGMDDSA-N 0.000 claims 1
- FMPJNBPZCVETGY-UHFFFAOYSA-N Pristimerinen Natural products C12=CC=C3C(C)=C(O)C(=O)C=C3C2=C(C)CC2(C)C1(C)CCC1(C)CCC(C(=O)OC)(C)CC12 FMPJNBPZCVETGY-UHFFFAOYSA-N 0.000 claims 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 235000007240 daidzein Nutrition 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 235000006539 genistein Nutrition 0.000 claims 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 1
- 229940045109 genistein Drugs 0.000 claims 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 235000003969 glutathione Nutrition 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 235000008800 isorhamnetin Nutrition 0.000 claims 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 claims 1
- 235000008777 kaempferol Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims 1
- 235000007743 myricetin Nutrition 0.000 claims 1
- 229940116852 myricetin Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- IXWGHMMOEFOOFA-UHFFFAOYSA-N pristimerin Natural products COC(=O)C1(C)CCC2(C)CCC3(C)C4CC=C5C(=C(O)C(=O)C=C5C4(C)CCC3(C)C2C1)C IXWGHMMOEFOOFA-UHFFFAOYSA-N 0.000 claims 1
- JFACETXYABVHFD-UHFFFAOYSA-N pristimerine Natural products CC1=C(O)C(=O)C=C2C(CCC3(C)C4(C)CCC5(C)CCC(CC53)(C)C(=O)OC)(C)C4=CC=C21 JFACETXYABVHFD-UHFFFAOYSA-N 0.000 claims 1
- 235000005875 quercetin Nutrition 0.000 claims 1
- 229960001285 quercetin Drugs 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Farmaceutski sastav koji sadrži kombinaciju oleoiletanolamida (OEA), β-aminoizobutirne kiseline (BAIBA) koji se prirodno javlja odabrane između valina i izoleucina i prirodnog antioksidansa.
2. Farmaceutski sastav sukladno patentnom zahtjevu 1, pri čemu količina oleoiletanolamida (OEA) je u rasponu od 10 do 70% tež. te supstance.
3. Farmaceutski sastav sukladno patentnom zahtjevu 1, pri čemu količina prirodne β-aminoizobutirne kiseline (BAIBA) je u rasponu od 2 do 60% tež. toga pripravka.
4. Farmaceutski sastav sukladno patentnom zahtjevu 1, pri čemu je prirodni antioksidans odabran iz vitamina E, glutationa, pantetina i fukoksantina.
5. Farmaceutski sastav sukladno za patentnom zahtjevu 4, pri čemu se količina prirodnog antioksidansa je u rasponu od 20% dto 35% tež. toga sastava.
6. Farmaceutski sastav sukladno patentnom zahtjevu 1, pri čemu ta kombinacija uključuje oleoiletanolamid (OEA), valin i pantetin.
7. Farmaceutski sastav sukladno patentnom zahtjevu 1, pri čemu taj sastav nadalje sadrži 1-deoksinojirimicin; FAAH inhibitor odabran između Quercetina, Myricetina, Isorhamnetina, Kaempferola, Pristimerina, Kurkumin, Biochanin A, Genistein i Daidzein ili njihova kombinacija.
8. Farmaceutski sastav sukladno patentnom zahtjevu 7, pri čemu količina 1-deoksinojirimicina je u rasponu od 0,5% do 1,5% tež. toga pripravka.
9. Farmaceutski sastav sukladno patentnom zahtjevu 7, pri čemu količina prirodnog FAAH inhibitora je u rasponu od 0,5% do 25% tež. toga sastava.
10. Farmaceutski sastav sukladno bilo kojem od prethodnih patentnih zahtjeva, nadalje sadrži farmaceutski prihvatljive ekscipijense.
11. Farmaceutski sastav za koju se zaštita patentom traži u patentnom zahtjevu 10, pri čemu su farmaceutski prihvatljivi ekscipijensi odabrani od razrjeđivača, veziva, maziva, lubrikanta i otapala.
12. Farmaceutski sastav za koju se zaštita patentom traži u patentnom zahtjevu 11, pri čemu količina razrjeđivača je u rasponu od 1% do 30% tež. toga sastava,
vezivnog sredstva je u rasponu od 0,5% do 1,5% tež. toga sastava,
lubrikanta je u rasponu od 0,5% do 5% tež. toga sastava,
maziva je u rasponu od 1,0% do 25% tež. toga sastava, ili
toga otapala je u dovoljnoj količini.
13. Farmaceutski sastav sukladno patentom zahtjevu 1, pri čemu je taj sastav u obliku tablete, kapsule, vrećica, pilule, tvrde kapsule napunjena tekućinom ili krutim sastavom, meke kapsule, praha, granule, suspenzije, otapala ili formulacije s modificiranim otpuštanjem.
14. Postupak za pripravu farmaceutskog sastava koji sadrži kombinaciju oleoiletanolamida (OEA), β-aminoizobutirne kiseline (BAIBA) koji se prirodno javlja odabran između valina i izoleucina i prirodnog antioksidansa, navedeni postupak obuhvaća:
a. pojedinačno vaganje oleoiletanolamida (OEA), prirodne β-aminoizobutirne kiseline (BAIBA) odabran između i izoleucina, prirodnog antioksidansa, razrjeđivača i glidansa u odvojenim spremnicima,
b. prosijavanje prethodno izvaganog oleoiletanolamida (OEA), prirodne β-aminoizobutirne kiseline (BAIBA) odabran između valina i izoleucina, prirodnog antioksidansa, razrjeđivač i glidans odvojeno,
c. miješanje sadržaja iz koraka b,
d. dobivanje otopine vezivnog sredstva u zasebnoj posudi i dodaje se u koraku c da bi se dobilo tijesto i prosijalo tijesto za dobivanje granula,
e. sušenje dobivenih granulata sve dok se razina suhoće (LOD) ne smanji na manje od 1,5 % m/m,
f. prosijavanje polusuhih granula kroz odgovarajuće sito, i
g. prosijavanje prethodno izvaganih lubrikanata ili maziva odvojeno kroz odgovarajuće sito i dodavanje u koraku f da bi se dobio sastav.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721029447 | 2017-08-19 | ||
| EP18188634.2A EP3443987B1 (en) | 2017-08-19 | 2018-08-13 | A pharmaceutical composition for prevention of diet induced obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210466T1 true HRP20210466T1 (hr) | 2021-05-14 |
Family
ID=63244444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210466TT HRP20210466T1 (hr) | 2017-08-19 | 2021-03-19 | Farmaceutski sastav za sprječavanje debljanja uzrokovanog načinom prehrane |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10702487B2 (hr) |
| EP (1) | EP3443987B1 (hr) |
| CA (1) | CA3012675C (hr) |
| CY (1) | CY1124010T1 (hr) |
| DK (1) | DK3443987T3 (hr) |
| EA (1) | EA201891651A3 (hr) |
| ES (1) | ES2864136T3 (hr) |
| HR (1) | HRP20210466T1 (hr) |
| HU (1) | HUE053678T2 (hr) |
| LT (1) | LT3443987T (hr) |
| MY (1) | MY177974A (hr) |
| PH (1) | PH12018000207A1 (hr) |
| PL (1) | PL3443987T3 (hr) |
| PT (1) | PT3443987T (hr) |
| RS (1) | RS61628B1 (hr) |
| SG (1) | SG10201806472SA (hr) |
| SI (1) | SI3443987T1 (hr) |
| UA (1) | UA122710C2 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041495A2 (en) * | 2019-08-26 | 2021-03-04 | The Trustees Of Indiana University | Method to maintain or enhance tissue |
| CN111084301B (zh) * | 2019-12-30 | 2023-08-22 | 内江师范学院 | 一种桑叶提取物鱼饲料粘合剂及制备方法和应用 |
| CN113712206A (zh) * | 2021-09-16 | 2021-11-30 | 湖南希尔天然药业有限公司 | 一种含有桑叶dnj和桑叶肽的组合物及其制备方法 |
| CA3242396A1 (en) * | 2021-12-13 | 2023-06-22 | The Regents Of The University Of California | Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide |
| WO2023250211A2 (en) * | 2022-06-24 | 2023-12-28 | Veroscience Llc | Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042687A (en) * | 1975-11-24 | 1977-08-16 | Control Drug, Inc. | Method of treating obesity by the oral administration of a predigested protein composition |
| US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
| CA2442683A1 (en) | 2001-03-27 | 2002-10-17 | The Regents Of The University Of California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
| AU2003296895A1 (en) | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
| WO2004045307A2 (en) | 2002-11-18 | 2004-06-03 | Natural Asa | Dietry supplements and foods product comprising oleylethanolamide |
| WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| EP1677780A4 (en) | 2003-10-16 | 2007-05-02 | Univ California | DIETETIC COMPOSITIONS AND OTHER COMPOSITIONS, COMPOUNDS AND METHODS FOR ORGANIC LIPID REDUCTION, APPETILE CONTROL, AND METABOLISM MODULATION OF FATTY ACIDS |
| US20090054526A1 (en) | 2005-07-14 | 2009-02-26 | Hansen Harald S | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders |
| WO2009093737A1 (ja) * | 2008-01-25 | 2009-07-30 | Kobayashi Pharmaceutical Co., Ltd. | 抗肥満用医薬組成物 |
| MX2010012682A (es) | 2008-05-19 | 2010-12-15 | Nestec Sa | Metodos para reducir la absorcion de lipidos por un animal. |
| WO2012015704A2 (en) | 2010-07-28 | 2012-02-02 | The Regents Of The University Of California | Peripherally restricted faah inhibitors |
| WO2012090225A2 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
| BR112013028723A2 (pt) | 2011-05-10 | 2016-08-09 | Nestec Sa | métodos e composições para promover o crescimento da massa corporal magra |
| MX354772B (es) | 2011-08-19 | 2018-03-21 | Univ California | Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido. |
| CN102579414A (zh) | 2012-01-29 | 2012-07-18 | 厦门大学 | 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途 |
| DK2890684T3 (en) | 2012-07-24 | 2018-05-07 | Bial Portela & Ca Sa | URINARY COMPOUNDS AND THEIR USE AS ENZYMINE INHIBITORS |
| WO2014037546A1 (en) | 2012-09-07 | 2014-03-13 | Nestec S.A. | Oleoylethanolamide compositions |
| ITMI20131180A1 (it) | 2013-07-15 | 2015-01-16 | Fond Istituto Italiano Di Tecnologia | O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah) |
| RU2693457C2 (ru) | 2013-07-18 | 2019-07-03 | Фондацьоне Иституто Итальяно Ди Текнолоджия | Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr) |
| HUE033615T2 (hu) | 2013-07-24 | 2017-12-28 | Bial - Portela & Ca S A | Imidazol-karboxamidok, és FAAH inhibitorként történõ alkalmazásuk |
| CN105593226A (zh) | 2013-08-01 | 2016-05-18 | 比亚尔-珀特拉和Ca股份公司 | 脲类化合物及其作为faah酶抑制剂的用途 |
| WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| IL305528A (en) | 2015-05-21 | 2023-10-01 | Scisparc Ltd | Combinations of opioids and acylethnoamines |
| WO2017025588A1 (en) | 2015-08-11 | 2017-02-16 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
-
2018
- 2018-07-26 US US16/046,482 patent/US10702487B2/en active Active
- 2018-07-27 MY MYPI2018702652A patent/MY177974A/en unknown
- 2018-07-27 CA CA3012675A patent/CA3012675C/en active Active
- 2018-07-30 SG SG10201806472SA patent/SG10201806472SA/en unknown
- 2018-07-31 PH PH12018000207A patent/PH12018000207A1/en unknown
- 2018-08-13 ES ES18188634T patent/ES2864136T3/es active Active
- 2018-08-13 PT PT181886342T patent/PT3443987T/pt unknown
- 2018-08-13 SI SI201830245T patent/SI3443987T1/sl unknown
- 2018-08-13 RS RS20210359A patent/RS61628B1/sr unknown
- 2018-08-13 EP EP18188634.2A patent/EP3443987B1/en active Active
- 2018-08-13 LT LTEP18188634.2T patent/LT3443987T/lt unknown
- 2018-08-13 HU HUE18188634A patent/HUE053678T2/hu unknown
- 2018-08-13 PL PL18188634T patent/PL3443987T3/pl unknown
- 2018-08-13 DK DK18188634.2T patent/DK3443987T3/da active
- 2018-08-16 EA EA201891651A patent/EA201891651A3/ru unknown
- 2018-08-16 UA UAA201808780A patent/UA122710C2/uk unknown
-
2021
- 2021-03-19 HR HRP20210466TT patent/HRP20210466T1/hr unknown
- 2021-03-23 CY CY20211100251T patent/CY1124010T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12018000207B1 (en) | 2019-06-03 |
| CA3012675A1 (en) | 2019-02-19 |
| EA201891651A3 (ru) | 2019-05-31 |
| PT3443987T (pt) | 2021-03-18 |
| CA3012675C (en) | 2021-06-15 |
| CY1124010T1 (el) | 2022-05-27 |
| PH12018000207A1 (en) | 2019-06-03 |
| BR102018016746A2 (pt) | 2019-03-26 |
| MY177974A (en) | 2020-09-28 |
| BR102018016746A8 (pt) | 2023-02-14 |
| EP3443987A1 (en) | 2019-02-20 |
| EA201891651A2 (ru) | 2019-02-28 |
| LT3443987T (lt) | 2021-04-26 |
| RS61628B1 (sr) | 2021-04-29 |
| SG10201806472SA (en) | 2019-03-28 |
| EP3443987B1 (en) | 2020-12-23 |
| PL3443987T3 (pl) | 2021-08-02 |
| SI3443987T1 (sl) | 2021-07-30 |
| UA122710C2 (uk) | 2020-12-28 |
| US20190054046A1 (en) | 2019-02-21 |
| US10702487B2 (en) | 2020-07-07 |
| DK3443987T3 (da) | 2021-03-22 |
| ES2864136T3 (es) | 2021-10-13 |
| HUE053678T2 (hu) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210466T1 (hr) | Farmaceutski sastav za sprječavanje debljanja uzrokovanog načinom prehrane | |
| HRP20200328T1 (hr) | Farmaceutski sastav za neuropatske boli | |
| HRP20191104T1 (hr) | Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu | |
| HRP20221105T1 (hr) | Farmaceutski sastav za anemiju | |
| JP2012031147A5 (hr) | ||
| WO2020044116A1 (en) | Therapeutic combinations of cannabinoids with curcumin | |
| JP2012031131A5 (hr) | ||
| RU2016152167A (ru) | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения | |
| EA200701401A1 (ru) | Состоящая из двух частей капсула с предварительным замком для фармацевтических препаратов и для применения в порошковых ингаляторах | |
| JP2022130534A (ja) | 経口組成物 | |
| CL2019002278A1 (es) | Proceso para el llenado gravimétrico en condiciones estériles de sólidos en un contenedor farmacéutico. | |
| MX2019010189A (es) | Polisulfato de pentosan, composicion farmaceutica y anticoagulante. | |
| IL285421A (en) | History of indazolyl-isoxazole, their preparation and pharmaceutical preparations containing them | |
| HRP20171485T1 (hr) | Farmaceutski pripravci koji sadrže alisporivir | |
| IN2014MU00327A (hr) | ||
| HRP20231360T1 (hr) | Mješavina biljnih ekstrakata za uporabu u prevenciji i/ili liječenju kroničnih upalnih bolesti crijeva | |
| CN106029077A (zh) | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 | |
| IL304247A (en) | History of spirocyclohexane, pharmaceutical preparations containing them and their use as anti-apoptotic inhibitors | |
| RU2020102280A (ru) | Фармацевтическая композиция и способ ее получения | |
| Khatri et al. | Formulation and evaluation of floating gastroretentive capsules of acyclovir with piperine as a bioenhancer | |
| RU2018101220A (ru) | Продукт на основе хелата бис-глицината железа и альгиновой кислоты и/или ее водорастворимых солей, его составы и его фармацевтические применения | |
| WO2021199463A1 (ja) | 経口組成物 | |
| BR112017004965A2 (pt) | aparelho para dosagem e embalagem de produtos agrícolas | |
| Afokoghene et al. | Formulation and Evaluation of Controlled Release Theophylline Tablets using Grewia spp Gum as Binder | |
| Akpabio et al. | Investigating Corchorus olitorius hydrocolloid as a novel matrix former in sustained release delivery of ibuprofen tablet |